US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

KraneShares MSCI All China Health Care Index ETF

18.54

-0.3850-2.03%

Post-market: 18.540.00000.00%19:30 EDT

Volume:64.75K

Turnover:1.20M

Market Cap:107.55M

PE:- -

High:18.87

Open:18.87

Low:18.44

Close:18.93

52wk High:21.88

52wk Low:14.38

Shares:5.80M

Float Shares:5.80M

Volume Ratio:2.51

T/O Rate:1.12%

Dividend:0.71

Dividend Rate:3.86%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Akeso FY26 H1 Net Loss Narrows 23.98% to RMB 447.2 Million; Revenue Rises 27.92% to RMB 1.81 Billion

Nomura Adjusts Innovent Biologics' Price Target to HK$125 From HK$105, Keeps at Buy

MT Newswires Live

China's CStone Pharmaceuticals H1 Revenue Soars on Drug Sales

CSPC Pharma Gets Trial Nod for Weight Management Drug in China

MT Newswires Live

CSPC Pharma's High-Activity Amylin Receptor Agonist Gets Green Light for Clinical Trials in China

CSPC Wins China Clinical Trial Approval for Syh2092 Amylin Agonist Injection

CSPC Pharmaceutical - Pharma Obtains China Clinical Trial Approval for Syh2092 Injection

THOMSON REUTERS

CSPC Pharmaceutical - Highly Potent Amylin Receptor Agonist (Syh2092 Injection) Obtains Clinical Trial Approval in China

THOMSON REUTERS

China's JW Therapeutics Interim Revenue Rises 4.7% on Carteyva Sales

Biocytogen Pharmaceuticals H1 Revenue up 51.6%

CSPC Pharmaceutical Group (SEHK:1093) Rallies Following Strong H1 Results As Valuation Stays In Focus

Simply Wall St.

Jefferies Boosts INNOVENT BIO Target to HK$125, Maintains Buy Rating

Innovent Biologics' Outlicensing Drug Deals Could Remain Key Share-Price Driver

China's Drug Regulator Accepts Novo Nordisk's Application for Oral Wegovy

Akeso Surges Over 6% Intraday as Guosen Securities Initiates 'Outperform' Rating

China's Jiangsu Says it Will Support Pharmaceutical Firms' Global M&A, Licensing

CSPC Pharma's Lung Cancer Candidate Meets Progression-Free Survival Primary Endpoint

MT Newswires Live

Beone Medicines' First-Half Profit Surges 386% as Core Drug Drives Revenue Past $3.2 Billion

VIVA Biotech H1 Profit Falls on Weaker Investment Income, FX Headwinds

Uni-Bio Science H1 Revenue Falls 12% on Pricing Changes

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/KURE/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"KURE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KURE\",,,,,undefined,":{"symbol":"KURE","market":"US","secType":"STK","nameCN":"KraneShares MSCI All China Health Care Index ETF","latestPrice":18.54,"timestamp":1788206400000,"preClose":18.925,"halted":0,"volume":64746,"hourTrading":{"tag":"盘后","latestPrice":18.54,"preClose":18.54,"latestTime":"19:30 EDT","volume":10,"amount":185.4,"timestamp":1788219002391,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.020343461030383172,"floatShares":5800979,"shares":5800979,"eps":0,"marketStatus":"Closed","change":-0.385,"latestTime":"08-31 16:00:00 EDT","open":18.87,"high":18.87,"low":18.44,"amount":1197156.0003479999,"amplitude":0.022721,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1788249600000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":18.925,"sharesOutstanding":4750002,"nav":19,"aum":110211439.71,"dividendRate":0.038554,"bidAskSpread":0.005823,"postHourTrading":{"tag":"盘后","latestPrice":18.54,"preClose":18.54,"latestTime":"19:30 EDT","volume":10,"amount":185.4,"timestamp":1788219002391,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":2.508893,"impliedVol":0.2767,"impliedVolPercentile":0.5737},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KURE\",,,,,undefined,":{"symbol":"KURE","floatShares":5800979,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":2.508893,"shares":5800979,"dividePrice":0.7148,"high":18.87,"amplitude":0.022721,"preClose":18.925,"low":18.44,"week52Low":14.3797,"pbRate":"--","week52High":21.875,"institutionHeld":0,"latestPrice":18.54,"eps":0,"divideRate":0.038554,"volume":64746,"delay":0,"ttmEps":0,"open":18.87,"prevYearClose":17.04,"prevWeekClose":18.925,"prevMonthClose":17.28,"prevQuarterClose":15.747,"fiveDayClose":18.6163,"twentyDayClose":17.0849,"sixtyDayClose":15.23},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KURE\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"KURE","amount":0.714689,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"KraneShares MSCI All China Health Care Index ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-23","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-23"},{"date":"2024-12-17","symbol":"KURE","amount":0.18361,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"KraneShares MSCI All China Health Care Index ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-18","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-18"},{"date":"2023-12-18","symbol":"KURE","amount":0.112844,"announcedDate":"2023-12-15","type":"dividend","market":"US","newRecordDate":"2023-12-19","defaultRemindTime":1702909800000,"name":"KraneShares MSCI All China Health Care Index ETF","recordDate":"2023-12-20","payableDate":"2023-12-19","currency":"USD","dateTimestamp":1702875600000,"payDate":"2023-12-20"},{"market":"US","date":"2022-12-28","symbol":"KURE","amount":0.010399,"defaultRemindTime":1672237800000,"name":"KraneShares MSCI All China Health Care Index ETF","recordDate":"2022-12-30","payableDate":"2022-12-29","currency":"USD","type":"dividend","dateTimestamp":1672203600000},{"market":"US","date":"2021-12-29","symbol":"KURE","amount":4.053448,"defaultRemindTime":1640788200000,"name":"KraneShares MSCI All China Health Care Index ETF","recordDate":"2021-12-31","payableDate":"2021-12-30","currency":"USD","type":"dividend","dateTimestamp":1640754000000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KURE\",market:\"US\",,,undefined,":[{"executeDate":"2018-12-26","recordDate":"2018-12-27","paymentDate":"2018-12-28","value":0.039344,"currency":"USD"},{"executeDate":"2019-12-27","recordDate":"2019-12-30","paymentDate":"2019-12-31","value":0.057325,"currency":"USD"},{"executeDate":"2020-12-29","recordDate":"2020-12-30","paymentDate":"2020-12-31","value":0.000109,"currency":"USD"},{"executeDate":"2021-12-29","recordDate":"2021-12-30","paymentDate":"2021-12-31","value":4.053448,"currency":"USD"},{"executeDate":"2022-12-28","recordDate":"2022-12-29","paymentDate":"2022-12-30","value":0.010399,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KURE\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KURE\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2662790083","title":"Akeso FY26 H1 Net Loss Narrows 23.98% to RMB 447.2 Million; Revenue Rises 27.92% to RMB 1.81 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2662790083","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662790083?lang=en_us&edition=fundamental","pubTime":"2026-08-27 22:00","pubTimestamp":1787839249,"startTime":"0","endTime":"0","summary":"Akeso FY26 H1 net loss narrows 23.98% to RMB 447.2 million; revenue rises 27.92% to RMB 1.81 billionAkeso posted revenue of RMB 1.81 billion, up 27.92% year over year, driven mainly by cadonilimab and","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL34jFkn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0561508036.HKD","LU1961090484.USD","LU2476274720.SGD","LU0348783233.USD","LU1720050803.USD","LU0348784397.USD","LU0348735423.USD","LU1794554557.SGD","IE00BPRC5H50.USD","LU0348766576.USD","LU0417516738.SGD","KURE","LU0348825331.USD","LU2399975544.HKD","BK1574","LU2488822045.USD","BK1161","LU0540923850.HKD","LU0348767384.USD","LU2778985437.USD","LU0348827113.USD","LU0634319403.HKD","LU0417516902.SGD","09926","IE00B543WZ88.USD","IE00B5MMRT66.SGD","LU0417516571.SGD","LU2476274308.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662980702","title":"Nomura Adjusts Innovent Biologics' Price Target to HK$125 From HK$105, Keeps at Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2662980702","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662980702?lang=en_us&edition=fundamental","pubTime":"2026-08-27 20:05","pubTimestamp":1787832345,"startTime":"0","endTime":"0","summary":"Innovent Biologics (HKG:1801) has an average rating of buy and mean price target of HK$127.43, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1969619763.USD","KURE","LU2097828714.EUR","01801","LU0455707207.USD","LU2328871848.SGD","LU2488822045.USD","LU2242644610.SGD","LU2097828557.USD","LU0326950275.SGD","LU1188198961.HKD","BK1583","LU0244354667.USD","LU2097828631.EUR","LU2097828474.EUR","HK0000165453.HKD","BK1589","BK1161","LU0502904849.HKD","LU0463099449.HKD","LU2097828805.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662046377","title":"China's CStone Pharmaceuticals H1 Revenue Soars on Drug Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2662046377","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662046377?lang=en_us&edition=fundamental","pubTime":"2026-08-27 19:40","pubTimestamp":1787830849,"startTime":"0","endTime":"0","summary":"China's CStone Pharmaceuticals H1 revenue soars on drug salesOverviewChina biopharma firm's half-year revenue rose 315% yr/yr to RMB205.1 mlnRevenue growth driven by higher pharmaceutical sales, espec","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nL1N44O0IS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK0216","688796","LU0502904849.HKD","01801","03692","LU2242644610.SGD","LU2097828474.EUR","HK0000165453.HKD","LU0244354667.USD","LU2097828714.EUR","BK1589","LU1188198961.HKD","LU2097828631.EUR","LU2488822045.USD","BK1574","LU0455707207.USD","LU0463099449.HKD","LU2097828557.USD","BK1161","LU2097828805.USD","LU2328871848.SGD","LU1969619763.USD","LU0326950275.SGD","BK1191","KURE","02616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662457709","title":"CSPC Pharma Gets Trial Nod for Weight Management Drug in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2662457709","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662457709?lang=en_us&edition=fundamental","pubTime":"2026-08-27 19:05","pubTimestamp":1787828740,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical Group  obtained clinical trial approval for the SYH2092 injection from China's National Medical Products Administration, according to a Thursday Hong Kong bourse filing.The product has the potential to bring significant clinical benefits for weight management in patients with obesity and improve glycaemic control in patients with type 2 diabetes mellitus.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE0008369823.USD","LU1152091754.HKD","LU1226287875.USD","IE00B031HY20.USD","KURE","LU1008478684.HKD","LU1152091168.USD","IE00BZ08YS42.EUR","LU1951186391.HKD","SG9999004220.SGD","LU0072913022.USD","LU1960683339.HKD","LU0501845795.SGD","LU1813983027.USD","LU1993786604.SGD","LU0315179316.USD","HK0000165453.HKD","BK1191","LU0880133367.SGD","IE00BZ08YR35.GBP","LU1226287792.SGD","LU1807302812.USD","IE00BZ08YT58.USD","BK1515","LU1226288253.USD","LU0314109678.HKD","LU1226288170.HKD","LU2039709279.SGD","LU1226287529.USD","LU1328277881.USD","IE00B5MMRT66.SGD","01093","LU0067412154.USD","IE0008368742.USD","IE00B543WZ88.USD","BK1521","LU0140636845.USD","LU0326950275.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191071495","title":"CSPC Pharma's High-Activity Amylin Receptor Agonist Gets Green Light for Clinical Trials in China","url":"https://stock-news.laohu8.com/highlight/detail?id=1191071495","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191071495?lang=en_us&edition=fundamental","pubTime":"2026-08-27 18:30","pubTimestamp":1787826628,"startTime":"0","endTime":"0","summary":"CSPC PHARMA (01093) has announced that its developed SYH2092 injection has received approval from China's National Medical Products Administration to proceed with clinical trials within the...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMED","IE00B031HY20.USD","LU1226287792.SGD","LU1813983027.USD","IE00BZ08YT58.USD","BK1191","LU2039709279.SGD","LU1008478684.HKD","01093","LU1993786604.SGD","LU0880133367.SGD","IE00BZ08YR35.GBP","LU1951186391.HKD","KURE","LU1807302812.USD","PSYK","IE00B543WZ88.USD","IE00BZ08YS42.EUR","LU0314109678.HKD","LU0501845795.SGD","LU1960683339.HKD","LU1226287529.USD","HK0000165453.HKD","LU1226288170.HKD","LU0067412154.USD","LU0315179316.USD","LU1226288253.USD","LU1152091754.HKD","BK1521","IBBJ","BK1515","LU1328277881.USD","LU0326950275.SGD","IE0008369823.USD","SG9999004220.SGD","LU0140636845.USD","LU1226287875.USD","IE0008368742.USD","IE00B5MMRT66.SGD","LU1152091168.USD","LU0072913022.USD","IBBQ","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662703286","title":"CSPC Wins China Clinical Trial Approval for Syh2092 Amylin Agonist Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2662703286","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662703286?lang=en_us&edition=fundamental","pubTime":"2026-08-27 18:19","pubTimestamp":1787825977,"startTime":"0","endTime":"0","summary":"CSPC wins China clinical trial approval for SYH2092 amylin agonist injectionCSPC won China NMPA clearance to start clinical trials of SYH2092, an amylin receptor agonist injection for obesity.Program ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL60gfrb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0501845795.SGD","IE0008368742.USD","LU0315179316.USD","IE00BZ08YS42.EUR","IE00B543WZ88.USD","LU0314109678.HKD","BK1521","LU0140636845.USD","01093","LU1960683339.HKD","LU0880133367.SGD","SG9999004220.SGD","LU1226287792.SGD","LU0326950275.SGD","IE00BZ08YT58.USD","LU1152091168.USD","IE0008369823.USD","LU1951186391.HKD","LU1813983027.USD","IE00B5MMRT66.SGD","LU1226288170.HKD","LU1993786604.SGD","BK1515","LU1226287529.USD","LU0072913022.USD","LU0067412154.USD","LU1226287875.USD","LU1152091754.HKD","LU1328277881.USD","LU1008478684.HKD","BK1191","LU1226288253.USD","LU1807302812.USD","IE00B031HY20.USD","LU2039709279.SGD","IE00BZ08YR35.GBP","KURE","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662703472","title":"CSPC Pharmaceutical - Pharma Obtains China Clinical Trial Approval for Syh2092 Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2662703472","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662703472?lang=en_us&edition=fundamental","pubTime":"2026-08-27 18:19","pubTimestamp":1787825949,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nFWN44O10A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1521","LU2039709279.SGD","LU1813983027.USD","LU1226288170.HKD","KURE","LU1328277881.USD","LU1993786604.SGD","LU0880133367.SGD","IE00B031HY20.USD","LU0314109678.HKD","BK1515","LU1807302812.USD","IE00B5MMRT66.SGD","IE0008369823.USD","LU0326950275.SGD","LU1960683339.HKD","LU1226287875.USD","LU1226287529.USD","IE00BZ08YS42.EUR","LU1226287792.SGD","LU1951186391.HKD","LU1226288253.USD","LU0140636845.USD","SG9999004220.SGD","IE00B543WZ88.USD","01093","LU1152091168.USD","IE0008368742.USD","LU0501845795.SGD","LU1152091754.HKD","HK0000165453.HKD","LU0067412154.USD","LU0072913022.USD","LU0315179316.USD","IE00BZ08YT58.USD","IE00BZ08YR35.GBP","BK1191","LU1008478684.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662471703","title":"CSPC Pharmaceutical - Highly Potent Amylin Receptor Agonist (Syh2092 Injection) Obtains Clinical Trial Approval in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2662471703","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662471703?lang=en_us&edition=fundamental","pubTime":"2026-08-27 18:19","pubTimestamp":1787825949,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nFWN44O10A:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2039709279.SGD","LU1993786604.SGD","HK0000165453.HKD","LU1152091754.HKD","LU1328277881.USD","IE00BZ08YT58.USD","KURE","LU1807302812.USD","LU1152091168.USD","SG9999004220.SGD","BK1515","LU0326950275.SGD","LU0072913022.USD","LU0315179316.USD","LU0140636845.USD","LU1226288253.USD","LU1226287529.USD","BK1191","IE00B031HY20.USD","IE00BZ08YR35.GBP","LU1951186391.HKD","LU0501845795.SGD","IE00B543WZ88.USD","LU1813983027.USD","IE0008369823.USD","LU1226287875.USD","IE00BZ08YS42.EUR","LU0067412154.USD","LU1960683339.HKD","LU1226288170.HKD","01093","BK1521","IE0008368742.USD","LU0314109678.HKD","IE00B5MMRT66.SGD","LU0880133367.SGD","LU1008478684.HKD","LU1226287792.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662708043","title":"China's JW Therapeutics Interim Revenue Rises 4.7% on Carteyva Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2662708043","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662708043?lang=en_us&edition=fundamental","pubTime":"2026-08-27 18:08","pubTimestamp":1787825320,"startTime":"0","endTime":"0","summary":"China's JW Therapeutics interim revenue rises 4.7% on Carteyva salesOverviewChina cell immunotherapy developer's interim revenue grew 4.7% yr/yr, driven by Carteyva salesGross profit margin improved t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nL1N44O0DW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1188198961.HKD","02126","LU0310799852.SGD","GLAM","IBB","PPH","01801","LU0949170772.SGD","IE0004445239.USD","IXJ","LU0868494617.USD","LU2362541513.USD","LU1934455863.HKD","JDOC","IE00BN8TJ469.HKD","LU0708994859.HKD","LU2237443382.USD","XLV","LU0859254822.USD","ABBV","REGN","IBBQ","LU0395794307.EUR","LU0463099449.HKD","RXL","LU1934455277.USD","CMI","FTXH","TBXU","IYH","TRUH","688331","LU0432979614.USD","MEDX","LU2237443978.SGD","VHT","LU1244550577.SGD","03692","IE00BVYPNV92.GBP","PJP","IE000SO60NU8.SGD","LU1037948897.HKD","LU2097828714.EUR","BBH","LU0943347566.SGD","BK1574","AGNG","FHLC","MADE","KURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662774568","title":"Biocytogen Pharmaceuticals H1 Revenue up 51.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662774568","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662774568?lang=en_us&edition=fundamental","pubTime":"2026-08-27 16:41","pubTimestamp":1787820113,"startTime":"0","endTime":"0","summary":"Biocytogen Pharmaceuticals H1 revenue up 51.6%OverviewChina biotech firm's H1 revenue rose 51.6% yr/yr to RMB941.4 mlnNet profit attributable to shareholders up 402.3% to RMB241.1 mlnCompany cites str","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nL1N44O0B0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","688796","LU0051755006.USD","01801","LU0502904849.HKD","LU3063872942.SGD","LU0359202008.SGD","LU0516422440.USD","LU0823426480.USD","03692","BK1521","LU0572944931.SGD","LU2097828474.EUR","LU1794554557.SGD","LU0244354667.USD","LU0823426308.USD","LU2039709279.SGD","IE00B0JY6N72.USD","LU0417516902.SGD","LU2097828631.EUR","LU0516422366.SGD","LU0140636845.USD","LU0819121731.USD","LU0128526141.USD","LU1880383366.USD","LU1242518857.USD","LU0417516738.SGD","LU2488822045.USD","LU0455707207.USD","LU0463099449.HKD","LU0588546209.SGD","LU1720050803.USD","LU0039217434.USD","LU0516423091.SGD","BK1576","LU0348735423.USD","LU0979878070.USD","LU0516423174.USD","BK1161","LU2097828805.USD","LU2328871848.SGD","LU0856984785.SGD","BK1191","LU0307460666.USD","02269","LU0456846285.SGD","KURE","LU0348825331.USD","02315","LU0320764599.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662977171","title":"CSPC Pharmaceutical Group (SEHK:1093) Rallies Following Strong H1 Results As Valuation Stays In Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2662977171","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662977171?lang=en_us&edition=fundamental","pubTime":"2026-08-27 15:20","pubTimestamp":1787815224,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical Group (SEHK:1093) is back in focus after reporting half year 2026 results, announcing a higher interim dividend and updating investors on several oncology drug milestones in China.\nThe recent half year 2026 earnings and oncology updates appear to have fed directly into CSPC Pharmaceutical Group’s share price momentum, with a 90 day share price return of 36.85% and a 30 day gain of 14.76% helping lift the stock to HK$9.525. The 3 year total shareholder return of 81.14%...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1093/cspc-pharmaceutical-group-shares/news/cspc-pharmaceutical-group-sehk1093-rallies-following-strong","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1093/cspc-pharmaceutical-group-shares/news/cspc-pharmaceutical-group-sehk1093-rallies-following-strong","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IE00B5MMRT66.SGD","DCF","IE00BZ08YT58.USD","FEBU","01093","JOYT","GXDW","IE00BZ08YS42.EUR","LU1328277881.USD","IE0008369823.USD","VGFPF","LU1226288253.USD","LU1960683339.HKD","IE00B031HY20.USD","IE00BZ08YR35.GBP","LU1813983027.USD","LU1951186391.HKD","LU0067412154.USD","SG9999004220.SGD","IE0008368742.USD","LU0326950275.SGD","PMDE","LU0072913022.USD","LU0880133367.SGD","LU1993786604.SGD","LU1226287529.USD","BK1515","HK0000165453.HKD","LU1152091754.HKD","LU1152091168.USD","LU1226287875.USD","LU1226288170.HKD","RGLO","LU0315179316.USD","LU2039709279.SGD","LU0140636845.USD","BK1191","VOTE","KURE","LU1008478684.HKD","IE00B543WZ88.USD","LU0314109678.HKD","LU1226287792.SGD","LU1807302812.USD","LU0501845795.SGD","DECU","BK1521"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133409443","title":"Jefferies Boosts INNOVENT BIO Target to HK$125, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=1133409443","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133409443?lang=en_us&edition=fundamental","pubTime":"2026-08-27 14:20","pubTimestamp":1787811619,"startTime":"0","endTime":"0","summary":"Jefferies has released a research report highlighting that INNOVENT BIO (01801) delivered robust sales in the first half of the year, alongside improved profitability. Management has expressed strong...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0326950275.SGD","LU0244354667.USD","LU2097828805.USD","BK1589","LU2097828631.EUR","LU2242644610.SGD","EWH","LU2097828714.EUR","LU2097828557.USD","KURE","LU2488822045.USD","LU0455707207.USD","LU0463099449.HKD","BK1583","LU0502904849.HKD","HK0000165453.HKD","LU1969619763.USD","LU2328871848.SGD","01801","LU1188198961.HKD","BK1161","LU2097828474.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662773368","title":"Innovent Biologics' Outlicensing Drug Deals Could Remain Key Share-Price Driver","url":"https://stock-news.laohu8.com/highlight/detail?id=2662773368","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662773368?lang=en_us&edition=fundamental","pubTime":"2026-08-27 14:01","pubTimestamp":1787810460,"startTime":"0","endTime":"0","summary":"0601 GMT - Innovent Biologics' outlicensing drug deals with multinational corporations could remain a key share-price driver, say DBS Group Research analysts in commentary. The Chinese biopharmaceutical company's previous deal with Pfizer in May boosted its stock by around 33% over two months. Innovent likely has around three early stage treatment products that could yield around $955 million in upfront payments, the analysts estimate. The company's balance sheet also remains strong, with net cash of around 16.2 billion yuan as of June, they add. DBS Group Research maintains its buy rating and 144.00 Hong Kong dollar target price. Shares drop 2.55% to HK$107.00.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1589","LU2488822045.USD","BK1161","BK1583","01801","LU1188198961.HKD","LU2097828474.EUR","LU2097828805.USD","KURE","LU2328871848.SGD","LU1969619763.USD","LU0244354667.USD","HK0000165453.HKD","LU2097828714.EUR","LU0455707207.USD","LU0502904849.HKD","LU2097828557.USD","LU2097828631.EUR","LU0326950275.SGD","LU0463099449.HKD","LU2242644610.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662727075","title":"China's Drug Regulator Accepts Novo Nordisk's Application for Oral Wegovy","url":"https://stock-news.laohu8.com/highlight/detail?id=2662727075","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662727075?lang=en_us&edition=fundamental","pubTime":"2026-08-27 12:42","pubTimestamp":1787805765,"startTime":"0","endTime":"0","summary":"UPDATE 2-China's drug regulator accepts Novo Nordisk's application for oral WegovySHANGHAI, Aug 27 (Reuters)-Novo NordiskNOVOb.COsaid on Thursday that China's drug regulator had accepted its applicati","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nL6N44O09E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2242644610.SGD","BK1589","KURE","IE000M9KFDE8.USD","LU0321505868.SGD","01801","IE00BLSP4239.USD","LU0463099449.HKD","IE00BBT3K403.USD","SG9999001176.USD","LU0502904849.HKD","LU2596442595.SGD","LU0225771236.USD","LU2328871848.SGD","BK4588","IE00B19Z3B42.SGD","LU0455707207.USD","SG9999002224.SGD","HK0000165453.HKD","LU0058720904.USD","LU0321505439.SGD","PFE","LU0122379950.USD","BK4568","LU2097828474.EUR","LU1894683264.USD","IE0002270589.USD","BK1583","BK1161","BK4599","SGXZ57979304.SGD","LU2097828631.EUR","BK4007","SG9999002232.USD","LU1057294990.SGD","LU0170899867.USD","SG9999011175.SGD","OZEM","LU0868494617.USD","IE00BLSP4452.SGD","LU1894683348.USD","BK4533","LU2097828557.USD","SG9999001176.SGD","00673","LU0456855351.SGD","BK4581","LU0985481810.HKD","IE00B19Z3581.USD","BK1197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185413400","title":"Akeso Surges Over 6% Intraday as Guosen Securities Initiates 'Outperform' Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=1185413400","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185413400?lang=en_us&edition=fundamental","pubTime":"2026-08-27 11:01","pubTimestamp":1787799711,"startTime":"0","endTime":"0","summary":"Akeso (09926) climbed more than 6% during Wednesday's trading session before paring gains, last up 2.34% at HK$96.40 with turnover reaching HK$686 million.On August 26, Akeso announced that its phase...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0276","LU0348767384.USD","LU0417516902.SGD","KURE","LU0348735423.USD","LU0634319403.HKD","LU0417516738.SGD","002736","LU0348766576.USD","LU0540923850.HKD","BK1574","LU2488822045.USD","BK0188","LU1794554557.SGD","BK0028","LU2778985437.USD","BK0183","IE00BPRC5H50.USD","BK1161","LU0348783233.USD","09926","IE00B5MMRT66.SGD","IE00B543WZ88.USD","LU0417516571.SGD","LU2399975544.HKD","LU1720050803.USD","LU1961090484.USD","LU0348825331.USD","LU0348827113.USD","LU0348784397.USD","LU0561508036.HKD","LU2476274720.SGD","LU2476274308.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662444718","title":"China's Jiangsu Says it Will Support Pharmaceutical Firms' Global M&A, Licensing","url":"https://stock-news.laohu8.com/highlight/detail?id=2662444718","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662444718?lang=en_us&edition=fundamental","pubTime":"2026-08-26 18:58","pubTimestamp":1787741906,"startTime":"0","endTime":"0","summary":"UPDATE 2-China's Jiangsu says it will support pharmaceutical firms' global M&A, licensingSHANGHAI, Aug 26 (Reuters)-Chinese biotech hub Jiangsu province pledged to support pharmaceutical companies see","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nL6N44N0KV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1589","LU2488822045.USD","LU2580892789.USD","BK1161","LU2580892862.HKD","BK1583","LU1255011170.USD","LU2289578879.USD","LU1328615791.USD","BK0060","LU0405327148.USD","01801","LU1997244956.HKD","LU1188198961.HKD","BK0012","LU2495084118.USD","LU2097828474.EUR","LU2097828805.USD","LU1997245177.USD","KURE","LU1146622755.USD","LU2328871848.SGD","LU1969619763.USD","LU0244354667.USD","HK0000165453.HKD","600276","LU1781817850.SGD","LU2097828714.EUR","LU0455707207.USD","BK0183","LU2148510915.USD","BK0196","LU0502904849.HKD","BK0188","LU1064131003.USD","LU2097828557.USD","LU0326950275.SGD","LU2097828631.EUR","LU1064130708.USD","LU1580142542.USD","BK0028","LU0463099449.HKD","LU2242644610.SGD","LU1997245094.SGD","BK0239","LU0405327494.USD","LU1655091616.SGD","LU1820825898.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662718144","title":"CSPC Pharma's Lung Cancer Candidate Meets Progression-Free Survival Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2662718144","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662718144?lang=en_us&edition=fundamental","pubTime":"2026-08-26 18:56","pubTimestamp":1787741807,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical Group  SYS6010 met the pre-specified primary endpoint of progression-free survival as reviewed by the Independent Data Monitoring Committee.The endpoint was reached in a phase III trial testing the product as a monotherapy versus platinum-based chemotherapy for non-small cell lung cancer, according to a Wednesday Hong Kong bourse filing.According to the results, the drug candidate's progression-free survival was significantly superior to existing treatment regimens, with high efficacy and favorable safety profile.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00B031HY20.USD","LU1226287792.SGD","LU1813983027.USD","IE00BZ08YT58.USD","BK1191","LU2039709279.SGD","LU1008478684.HKD","01093","LU1993786604.SGD","LU0880133367.SGD","IE00BZ08YR35.GBP","LU1951186391.HKD","KURE","LU1807302812.USD","IE00B543WZ88.USD","IE00BZ08YS42.EUR","LU0314109678.HKD","LU0501845795.SGD","LU1960683339.HKD","LU1226287529.USD","HK0000165453.HKD","LU1226288170.HKD","LU0067412154.USD","LU0315179316.USD","LU1226288253.USD","LU1152091754.HKD","BK1521","BK1515","LU1328277881.USD","LU0326950275.SGD","IE0008369823.USD","SG9999004220.SGD","LU0140636845.USD","LU1226287875.USD","IE0008368742.USD","IE00B5MMRT66.SGD","LU1152091168.USD","LU0072913022.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141434847","title":"Beone Medicines' First-Half Profit Surges 386% as Core Drug Drives Revenue Past $3.2 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1141434847","media":"Deep News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141434847?lang=en_us&edition=fundamental","pubTime":"2026-08-26 18:44","pubTimestamp":1787741086,"startTime":"0","endTime":"0","summary":"Beone Medicines has delivered a stellar first-half performance for fiscal 2026, with profitability climbing sharply year-on-year and validating the effectiveness of its commercial strategy.According...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0307460666.USD","LU1719994722.HKD","LU2328871848.SGD","BK4588","BK1500","LU0588546209.SGD","ONC","LU1969619763.USD","LU1251922891.USD","BK1588","BK1161","LU1303224171.USD","BK4585","KURE","LU0228659784.USD","BK0239","BK1583","BK4526","06160","BK4139","688235","LU0828237510.HKD","LU1770034418.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662909757","title":"VIVA Biotech H1 Profit Falls on Weaker Investment Income, FX Headwinds","url":"https://stock-news.laohu8.com/highlight/detail?id=2662909757","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662909757?lang=en_us&edition=fundamental","pubTime":"2026-08-26 18:34","pubTimestamp":1787740471,"startTime":"0","endTime":"0","summary":"VIVA Biotech H1 profit falls on weaker investment income, FX headwindsOverviewChina-based biopharma services provider's H1 revenue rose 21% yr/yr, driven by CDMO businessNet profit and adjusted non-IF","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nL1N44N0DO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1576","LU0326950275.SGD","LU3063872942.SGD","LU1880383366.USD","LU0823426480.USD","LU0051755006.USD","BK1141","LU0819121731.USD","LU0029874061.USD","LU0320764599.SGD","LU0516422366.SGD","LU1688375341.USD","LU0516422440.USD","LU1794554557.SGD","BK1521","LU0181495838.USD","01873","LU0327786744.USD","SG9999002463.SGD","LU0359202008.SGD","LU0456827905.SGD","BK1610","LU0128526141.USD","BK1589","LU0043850808.USD","LU0417516902.SGD","LU0516423091.SGD","LU0979878070.USD","LU1242518931.SGD","LU0856984785.SGD","LU0359201612.USD","LU1242518857.USD","LU0516423174.USD","LU0417516738.SGD","LU0456846285.SGD","LU0039217434.USD","LU0348825331.USD","KURE","02269","LU0140636845.USD","IE00B0JY6N72.USD","LU0516422952.EUR","LU0052750758.USD","LU0708995583.HKD","LU2039709279.SGD","LU1720050803.USD","LU0588546209.SGD","LU0348735423.USD","SG9999002562.SGD","LU0307460666.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662797145","title":"Uni-Bio Science H1 Revenue Falls 12% on Pricing Changes","url":"https://stock-news.laohu8.com/highlight/detail?id=2662797145","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662797145?lang=en_us&edition=fundamental","pubTime":"2026-08-26 18:18","pubTimestamp":1787739506,"startTime":"0","endTime":"0","summary":"Uni-Bio Science H1 revenue falls 12% on pricing changesOverviewHong Kong-listed biopharma firm's H1 2026 revenue fell 12% yr/yr amid pricing adjustmentsNet profit dropped 59% as R+D and commercializat","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nL1N44N0D4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE000MB6IJN5.SGD","LU0203347892.USD","MEDX","LU2129689605.HKD","LU2133065610.SGD","IE00B2B36J28.USD","AGNG","IE00BSNM7G36.USD","IE000BZT7R73.USD","LU0868494708.USD","IE0009355771.USD","ABBV","XLV","KURE","FTXH","FHLC","LU2347655073.USD","SG9999015986.USD","LU0820561909.HKD","LU0122379950.USD","IE0002270589.USD","IXJ","LU1989772840.SGD","GLAM","LU0211328371.USD","00690","688331","JDOC","BK4581","LU0234572021.USD","03692","BK1191","IE00BLSP4452.SGD","LU1934455277.USD","LU0057025933.USD","IE000WAW04H5.SGD","IE00B19Z3581.USD","PPH","VHT","LU0211327993.USD","RXL","BK1583","IYH","BK4588","LU0985320562.USD","01801","PJP","TRUH","BK4533","LU0203345920.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":2,"totalSize":200,"code":"91000000","status":"200"}]}}